The Clinical Pharmacogenetics Implementation Consortium, an international consortium interested in facilitating pharmacogenetic test use, also supported HLA-B*58:01 testing, especially in Asian population, to reduce the incidence and risk of allopurinol-induced SCAR [13]. The gene discussed is HLA-B; the disease is Scarring.